An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission

CONCLUSIONS: MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses.PMID:34667029 | DOI:10.1158/1078-0432.CCR-21-1916

Source: Clinical Cancer Research - October 20, 2021 Category: Cancer & Oncology Authors: Luca Biavati Carol Ann Huff Anna Ferguson Amy Sidorski M Amanda Stevens Lakshmi Rudraraju Cristina Zucchinetti Syed Abbas Ali Philip Imus Christian B Gocke Rachel M Gittelman Sarah Johnson Catherine Sanders Marissa Vignali Anita Gandhi Xiaobu Ye Kimberly Source Type: research